Your browser doesn't support javascript.
loading
Safety and Efficacy of High Power Shorter Duration Ablation Guided by Ablation Index or Lesion Size Index in Atrial Fibrillation Ablation: A Systematic Review and Meta-Analysis.
Liu, Xing; Gui, Chun; Wen, Weiming; He, Yan; Dai, Weiran; Zhong, Guoqiang.
Affiliation
  • Liu X; Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530000, Guangxi, China.
  • Gui C; Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530000, Guangxi, China.
  • Wen W; Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530000, Guangxi, China.
  • He Y; Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530000, Guangxi, China.
  • Dai W; Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530000, Guangxi, China.
  • Zhong G; Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530000, Guangxi, China.
J Interv Cardiol ; 2021: 5591590, 2021.
Article in En | MEDLINE | ID: mdl-34149322
ABSTRACT

BACKGROUND:

High power shorter duration (HPSD) ablation may lead to safe and rapid lesion formation. However, the optimal radio frequency power to achieve the desired ablation index (AI) or lesion size index (LSI) is insubstantial. This analysis aimed to appraise the clinical safety and efficacy of HPSD guided by AI or LSI (HPSD-AI or LSI) in patients with atrial fibrillation (AF).

METHODS:

The Medline, PubMed, Embase, Web of Science, and the Cochrane Library databases from inception to November 2020 were searched for studies comparing HPSD-AI or LSI and low power longer duration (LPLD) ablation.

RESULTS:

Seven trials with 1013 patients were included in the analysis. The analyses verified that HPSD-AI or LSI revealed benefits of first-pass pulmonary vein isolation (PVI) (RR 1.28; 95% CI 1.05-1.56, P = 0.01) and acute pulmonary vein reconnection (PVR) (RR 0.65; 95% CI 0.48-0.88, P = 0.005) compared with LPLD. HPSD-AI or LSI showed higher freedom from atrial tachyarrhythmia (AT) (RR = 1.32, 95% CI 1.14-1.53, P = 0.0002) in the subgroup analysis of studies with PVI ± (with or without additional ablation beyond PVI). HPSD-AI or LSI could short procedural time (WMD -22.81; 95% CI, -35.03 to -10.60, P = 0.0003), ablation time (WMD -10.80; 95% CI -13.14 to -8.46, P < .00001), and fluoroscopy time (WMD -7.71; 95% CI -13.71 to -1.71, P = 0.01). Major complications and esophageal lesion in HPSD-AI or LSI group were no more than LDLP group (RR 0.58; 95% CI 0.20-1.69, P = 0.32) and (RR 0.84; 95% CI 0.43-1.61, P = 0.59).

CONCLUSIONS:

HPSD-AI or LSI was efficient for treating AF with shorting procedural, ablation, and fluoroscopy time, higher first-pass PVI, and reducing acute PVR and may increase freedom from AT for patients with additional ablation beyond PVI compared with LPLD. Moreover, complications and esophageal lesion were low and no different between two groups.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Atrial Fibrillation / Catheter Ablation / Duration of Therapy Type of study: Systematic_reviews Limits: Humans Language: En Journal: J Interv Cardiol Journal subject: CARDIOLOGIA Year: 2021 Document type: Article Affiliation country: China Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Atrial Fibrillation / Catheter Ablation / Duration of Therapy Type of study: Systematic_reviews Limits: Humans Language: En Journal: J Interv Cardiol Journal subject: CARDIOLOGIA Year: 2021 Document type: Article Affiliation country: China Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA